Skip to Main Content
Addictive Behaviors | HIV/AIDS | Infectious Diseases

Impact of HIV Infection on Immunologic, Transcriptomic, and Metabolomic Signatures

What is the purpose of this trial?

The purpose of this study is to understand changes in how your blood cells, genes, metabolism, and immune system work after you begin medication assisted therapy (MAT) (e.g. buprenorphine/naloxone, buprenorphine, methadone or extended-release naltrexone), for treatment of an opioid use disorder. The researchers will follow all participants and schedule regular interviews and blood draws to gather information. This will enable them to look at the presence of specific factors associated with treatment for opioid use disorder in those living with HIV infection and those without HIV infection. The study will last for 6 months.

  • Trial with
    National Institute on Drug Abuse (NIDA)
  • Ages
    18 years and older
  • Gender
    Both

Contact Information

For more information about this study, including how to volunteer, contact Victor Neirinckx

Help Us Discover!

You can help our team find trials you might be eligible for by creating a volunteer profile in MyChart. To get started, create a volunteer profile, or contact helpusdiscover@yale.edu, or call 877.978.8343 for more information.

  • Last Updated
    02/01/2024
  • Study HIC
    #1608018239